Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on developing immunotherapy treatments for cancer. Its lead product candidate, monalizumab, targets the NKG2A receptor and is in clinical trials for various cancers, including head and neck squamous cell carcinoma. The company's unique approach leverages its proprietary technology platform to enhance immune responses against tumors.
Innate Pharma primarily generates revenue through partnerships and collaborations with larger pharmaceutical companies, which provide funding for clinical trials in exchange for rights to commercialize successful therapies. The company has no current product sales, making it heavily reliant on external funding and milestones from partnerships.
Progress in clinical trials for monalizumab, particularly in head and neck cancer
Partnership announcements or collaborations with larger pharmaceutical companies
Regulatory approvals or advancements in trial phases
Market sentiment towards immunotherapy advancements
Regulatory changes that could impact drug approval processes
Technological disruption in cancer treatment methodologies
Emerging immunotherapies from competitors that could overshadow monalizumab
Potential for larger pharmaceutical companies to develop similar therapies in-house
High operating losses leading to potential liquidity issues
Dependence on external funding sources for R&D
low - The biotechnology sector is generally less sensitive to economic cycles, as demand for healthcare remains relatively stable regardless of economic conditions.
Moderate - Rising interest rates could increase the cost of capital for funding clinical trials, potentially impacting the company's ability to finance operations.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on debt financing.
growth - Investors looking for high-risk, high-reward opportunities in the biotechnology sector.
high - The stock has exhibited significant volatility, reflective of the high-risk nature of clinical-stage biotechnology companies.
